This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Helicos BioSciences Amends Patent Infringement Lawsuit Against Pacific Biosciences To Include Illumina And Life Technologies

Helicos BioSciences Corporation (NASDAQ: HLCS) announced today that it has amended its lawsuit against Pacific Biosciences of California, Inc. for patent infringement by naming Illumina, Inc. and Life Technologies Corporation as additional defendants. The amended lawsuit, Helicos BioSciences Corporation v. Pacific Biosciences of California, Inc., Life Technologies Corporation, and Illumina, Inc., No. 1:10-cv-00735, filed in the United States District Court for the District of Delaware, alleges that the companies willfully infringe Helicos’ patents for sequencing-by-synthesis methods. The suit seeks injunctive relief and monetary damages.

"These actions further support our recently announced strategic initiative to maximize the return to our shareholders on the technology investments that we have made by vigorously protecting our seminal next-generation sequencing intellectual property rights. Helicos was the first to invent and market single molecule sequencing technology and has established a foundational patent estate with the earliest priority dates in the field,” stated Dr. Ivan Trifunovich, President and CEO of Helicos. “After a careful examination of the sequencing products and technologies offered by Illumina and Life Technologies, we are convinced that they, in addition to Pacific Biosciences, infringe the Helicos patents, which are in full force and effect up through 2028.”

The complaint alleges infringement of U.S. Patent Nos. 7,645,596 (which expires in 2019), 7,037,687 (which expires in 2020), 7,169,560 (which expires in 2024), 7,767,400 (which expires in 2028) and 7,593,109 (which expires in 2024). Collectively, these patents broadly cover key features of sequencing-by-synthesis technology. In the case, Helicos claims that all three companies incorporated Helicos’ patented sequencing-by-synthesis technology into their respective sequencing systems and products. The patents cover sequencing-by-synthesis methods using labeled nucleotides. The nucleotides are labeled with detectable markers, such as fluorescent markers, that enable determination of each nucleotide incorporated into the DNA strand being extended by the polymerase. The patents describe processes that involve, for example, identifying each new nucleotide by observing its detectable label and neutralizing or removing the label before addition of the next nucleotide. The specific claims apply to both “real time” and “step and repeat” approaches. Helicos believes that these fundamental, patented sequencing-by-synthesis and sample detection technologies are at the heart of the defendants’ sequencing technology platforms, all of which infringe multiple claims in several patents, as asserted in the complaint. In addition, Helicos claims that Illumina’s critical detection components in their sequencing instruments Genome Analyzer and HiSeq 2000 infringe on Helicos’ patent 7,593,109.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,686.25 +329.38 1.90%
S&P 500 2,050.44 +37.55 1.87%
NASDAQ 4,730.3260 +86.0140 1.85%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs